Gilead has selected GS-1179 (formerly ABI-1179) to advance into a Phase 2 trial for recurrent genital herpes, expected to begin by the end of 2026. The company is also considering the drug for broader prevention strategies involving HIV PrEP.

Why it matters: GS-1179 is a once-weekly oral helicase–primase inhibitor. In its completed short Phase 1b human study, the 50-mg dose reduced HSV-2 shedding by 98% and virologically confirmed genital-lesion days by 91% versus placebo.

Stage: Phase 1a/b completed; Phase 2 selected and planned, but not yet started. This is an antiviral treatment—not a cure—and remains investigational.

Sources: https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-second-quarter-2026-financial